
Veraxa Biotech AG - Post de-SPAC
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Veraxa Biotech AG develops antibody-drug conjugates and other targeted biologic therapies for cancer treatment, using its proprietary protein engineering platforms to design antibodies aimed at tumor-specific targets.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Ziegler Christoph SamuelDirector | Buy | $33K | 30,000at $1.09 | Oct 20, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable VRXA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.